Product Information
LAMOTRIGINE ER 250 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $1.3026 per EA under NDC 31722024430. Its NADAC has been published 191 times since Feb 8, 2023.
FDA first approved this application on Dec 8, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722024430
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMOTRIGINEApproval Type
Generic (ANDA)
FDA Application
ANDA213949FDA Approved
12/8/2021
TE Code
AB
On Market Since
12/9/2021
Pharmacological Classes
Price Statistics
The NADAC for LAMOTRIGINE ER 250 MG TABLET has been published 191 times since Feb 8, 2023, and over the history we have for it it has declined 69.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3026 per EA |
|---|---|
| All-time high | $4.2366 (Feb 15, 2023) |
| All-time low | $1.1070 (Nov 19, 2025) |
| 52-week high | $1.3127 |
| 52-week low | $1.1070 |
| Median price | $1.7648 |
| Average price | $1.9430 |
| Largest weekly change | +56.5% (Aug 21, 2024) |
| Weeks tracked | 191 |
| Tracking since | Feb 8, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lamotrigine extended-release market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lamotrigine extended-release market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMOTRIGINE ER 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMOTRIGINE ER 250 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $1.3026 per EA (NDC 31722024430), effective Sep 30, 2026.
How has the price of LAMOTRIGINE ER 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMOTRIGINE ER 250 MG TABLET has declined 69.3%. It has been tracked across 191 weekly CMS publications since Feb 8, 2023.
What are the highest and lowest recorded NADAC prices for LAMOTRIGINE ER 250 MG TABLET?
Since Feb 8, 2023, the NADAC for LAMOTRIGINE ER 250 MG TABLET has ranged from a low of $1.1070 (Nov 19, 2025) to a high of $4.2366 (Feb 15, 2023), with a median of $1.7648 per EA.
Are there cheaper alternatives to LAMOTRIGINE ER 250 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LAMOTRIGINE ER 250 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAMOTRIGINE ER 250 MG TABLET?
LAMOTRIGINE ER 250 MG TABLET (NDC 31722024430) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.